Plasma concentrations of quetiapine, N-desalkylquetiapine, O-desalkylquetiapine, 7-hydroxyquetiapine, and quetiapine sulfoxide in relation to quetiapine dose, formulation, and other factors

Therapeutic Drug Monitoring

Volumn 34, Issue 4, 2012, Pages 415-421

  Fisher, Danielle S ^a   Handley, Simon A ^a   Flanagan, Robert J ^a   Taylor, David M ^b  

^a KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

N desalkylquetiapine; pharmacokinetics; quetiapine; quetiapine sulfoxide; therapeutic drug monitoring

Indexed keywords

7 HYDROXYQUETIAPINE; DRUG METABOLITE; N DESALKYLQUETIAPINE; O DESALKYLQUETIAPINE; QUETIAPINE; QUETIAPINE SULFOXIDE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG METABOLISM; DRUG MONITORING; DRUG RELEASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; SEX DIFFERENCE; TREATMENT REFUSAL;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CHEMISTRY, PHARMACEUTICAL; DIBENZOTHIAZEPINES; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; SAFROLE; SEX FACTORS; YOUNG ADULT;

EID: 84863840559     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3182603f62     Document Type: Article

References (43)

1. Wang Z, Kemp DE, Chan PK, et al. Comparisons of the tolerability and sensitivity of quetiapine-XR in the acute treatment of schizophrenia, bipolar mania, bipolar depression, major depressive disorder, and generalized anxiety disorder. Int J Neuropsychopharmacol. 2011;14:131-142.
2. Rasmussen H, Ebdrup BH, Erritzoe D, et al. Serotonin2A receptor blockade and clinical effect in first-episode schizophrenia patients treated with quetiapine. Psychopharmacology (Berl). 2011;213:583-592.
3. Sparshatt A, Taylor D, Patel MX, et al. Relationship between daily dose, plasma concentrations, dopamine receptor occupancy, and clinical response to quetiapine: a review. J Clin Psychiatry. 2011:72:1108-1123.
4. Al Jurdi RK, Dixit LA, Sajatovic M. Role of extended release quetiapine in the management of bipolar disorders. Neuropsychiatr Dis Treat. 2010;6:29-35.
5. Dell'Osso B, Palazzo MC, Oldani L, et al. The noradrenergic action in antidepressant treatments: pharmacological and clinical aspects. CNS Neurosci Ther. 2010;17:723-732.
6. Gedge L, Lazowski L, Murray D, et al. Effects of quetiapine on sleep architecture in patients with unipolar or bipolar depression. Neuropsychiatr Dis Treat. 2010;6:501-508.
7. Jensen NH, Rodriguiz RM, Caron MG, et al. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1a agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology. 2008;33:2303-2312.
8. Chen J, Gao K, Kemp DE. Second-generation antipsychotics in major depressive disorder: update and clinical perspective. Curr Opin Psychiatry. 2011;24:10-17.
9. Bandelow B, Chouinard G, Bobes J, et al. Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo-and active-controlled study. Int J Neuropsychopharmacol. 2010;13:305-320.
10. Bauer M, El-Khalili N, Datto C, et al. A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder. J Affect Disord. 2010;127:19-30.
11. El-Khalili N, Joyce M, Atkinson S, et al. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2010;13:917-932.
12. Liebowitz M, Lam RW, Lepola U, et al. Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial. Depress Anxiety. 2010;27:964-976.
13. Shajahan P, Taylor M. The uses and outcomes of quetiapine in depressive and bipolar mood disorders in clinical practice. J Psychopharmacol. 2010;24:565-572.
14. Soares CN, Frey BN, Haber E, et al. A pilot, 8-week, placebo lead-in trial of quetiapine extended release for depression in midlife women: impact on mood and menopause-related symptoms. J Clin Psychopharmacol. 2010:30:612-615.
15. Anderson IM, Sarsfield A, Haddad PM. Efficacy, safety and tolerability of quetiapine augmentation in treatment resistant depression: an open-label, pilot study. J Affect Disord. 2009;117:116-119.
16. Bogart GT, Chavez B. Safety and efficacy of quetiapine in bipolar depression. Ann Pharmacother. 2009;43:1848-1856.
17. Olver JS, Ignatiadis S, Maruff P, et al. Quetiapine augmentation in depressed patients with partial response to antidepressants. Hum Psychopharmacol. 2008;23:653-660.
18. Mauri M, Volonteri L, Fiorentini A, et al. Two week's quetiapine treatment for schizophrenia, drug-induced psychosis and borderline personality disorder: a naturalistic study with drug plasma levels. Expert Opin Pharmacother. 2007;8:2207-2213. (Pubitemid 350001584)
19. Vieta E, Calabrese JR, Goikolea JM, et al. Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapidcycling disease course: a randomized, double-blind, placebo-controlled study. Bipolar Disord. 2007;9:413-425. (Pubitemid 46865372)
20. Bakken GV, Rudberg I, Molden E, et al. Pharmacokinetic variability of quetiapine and the active metabolite N-desalkylquetiapine in psychiatric patients. Ther Drug Monit. 2011;33:222-226.
21. DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet. 2001;40:509-522.
22. Figueroa C, Brecher M, Hamer-Maansson JE, et al. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:199-204.
23. Winter HR, Earley WR, Hamer-Maansson JE, et al. Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders. J Child Adolesc Psychopharmacol. 2008;18:81-98. (Pubitemid 351311245)
24. Nemeroff CB, Kinkead B, Goldstein J. Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. J Clin Psychiatry. 2002;63:5-11. (Pubitemid 35471364)
25. Hasselstrom J, Linnet K. Quetiapine serum concentrations in psychiatric patients - the influence of comedication. Ther Drug Monit. 2004;26:486-491. (Pubitemid 39314315)
26. Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol. 2007;100:4-22. (Pubitemid 46051438)
27. Bakken GV, Rudberg I, Christensen H, et al. Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of cytochrome B5. Drug Metab Dispos. 2009;37:254-258.
28. Nikisch G, Baumann P, Oneda B, et al. Cytochrome P450 and ABCB1 genetics: association with quetiapine and norquetiapine plasma and cerebrospinal fluid concentrations and with clinical response in patients suffering from schizophrenia. A pilot study. J Psychopharmacol. 2011;25:896-907.
29. Di Benedetto B, Kühn R, Nothdurfter C, et al. N-desalkylquetiapine activates ERK1/2 to induce GDNF release in C6 glioma cells: a putative cellular mechanism for quetiapine as antidepressant. Neuropharmacology. 2012;62:209-216.
30. Fisher DS, Handley SA, Taylor D, et al. Measurement of quetiapine and four quetiapine metabolites in human plasma by LC-MS/MS. Biomed Chromatogr. 2012; doi: 10.1002/bmc.2672.
31. Hiemke C, Baumann P, Bergemann N, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry. 2011;44:195-235.
32. Aichhorn W, Marksteiner J, Walch T, et al. Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations. Int Clin Psychopharmacol. 2006;21:81-85. (Pubitemid 43740314)
33. Castberg I, Skogvoll E, Spigset O. Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service. J Clin Psychiatry. 2007;68:1540-1545. (Pubitemid 350073402)
34. Nikisch G, Baumann P, Kießling B, et al. Relationship between dopamine D2 receptor occupancy, clinical response, and drug and monoamine metabolites levels in plasma and cerebrospinal fluid. A pilot study in patients suffering from first-episode schizophrenia treated with quetiapine. J Psychiatr Res. 2010;44:754-759.
35. Li KY, Li X, Cheng ZN, et al. Multiple dose pharmacokinetics of quetiapine and some of its metabolites in Chinese suffering from schizophrenia. Acta Pharmacol Sin. 2004;25:390-394. (Pubitemid 38316053)
36. McElroy SL, Weisler RH, Chang W, et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry. 2010;71:163-174.
37. Young AH, McElroy SL, Bauer M, et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry. 2010;71:150-162.
38. Bauer M, Pretorius HW, Constant EL, et al. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry. 2009;70:540-549.
39. Depping AM, Komossa K, Kissling W, et al. Second-generation antipsychotics for anxiety disorders. Cochrane Database Syst Rev. 2010;8:CD008120.
40. Altamura AC, Serati M, Buoli M, et al. Augmentative quetiapine in partial/nonresponders with generalized anxiety disorder: a randomized, placebo-controlled study. Int Clin Psychopharmacol. 2011; 26:201-205.
41. Zhornitsky S, Potvin S, Moteshafi H, et al. Dose-response and comparative efficacy and tolerability of quetiapine across psychiatric disorders: a systematic review of the placebo-controlled monotherapy and add-on trials. Int Clin Psychopharmacol. 2011;26:183-192.
42. Suppes T, Datto C, Minkwitz M, et al. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. J Affect Disord. 2010;121:106-115.
43. Kornhuber J, Weigmann H, Röhrich J, et al. Region specific distribution of levomepromazine in the human brain. J Neural Transm. 2006;113:387-397. (Pubitemid 43201105)